Company profile
Elixxer Ltd.
OTC: ELIXF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Montreal, QCReports USD
#1166 of 1,422 Healthcare companies by revenue
EA Score
14DFH 9DQ —GM 15SS 41
v0.1 · 45/100 weight · provisional
↑ disclosure history, listing tenure · ↓ 3-yr revenue growth, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$2.8M
Employees
—
as of 2026-08-21
Market cap
$3.2M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2025
Net income-$2.8M-3.9M CAD2025
Operating income-$476.0k-665.4k CAD2025
Total assets$775.6k1.1M CAD2025
Liabilities$8.1M11.1M CAD2025
Equity-$7.3M-10.0M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Elixxer Ltd.’s revenue?
Elixxer Ltd. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
PharmaTher Holdings Ltd.——Quest PharmaTech Inc.——nDatalyze Corp.47DMoleculin Biotech, Inc.42DMedican Enterprises, Inc.——Autonomix Medical, Inc.28DKey facts
CEOKarim Mecklai
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersMontreal, QC
ExchangeOTC: ELIXF
Employees—
IPO date2017-12-14
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.